6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
Just now	Appendix 4C and Quarterly Activities Report - March 2026
Just now	Landis+Gyr Announces Sale of Rhebo to Everfield
1m ago	Lazard to Acquire Campbell Lutyens, Creating the Global Leader in Private Capital Advisory
11m ago	2026 ESMO GC \| Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
23m ago	Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025

About

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) — investor relations, events, news, and company updates on 6ix.

Latest News

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Financials

Revenue

$0

Market Cap

$3.55 M

EPS

-2.39

Community Chat

Ask AI